Marginal Zone B-Cell Lymphoma
Information
- Disease name
- Marginal Zone B-Cell Lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02722668 | Active, not recruiting | Phase 2 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | May 15, 2017 | December 2029 |
| NCT01164267 | Completed | Phase 2 | Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) | March 2010 | |
| NCT00783367 | Completed | Phase 2 | Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas | July 2008 | November 23, 2020 |
| NCT02433795 | Completed | Phase 2 | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) | May 2015 | October 2019 |
| NCT02853370 | Completed | Phase 2 | Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma | July 2012 | December 2020 |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT02991898 | Terminated | Phase 2 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | February 16, 2017 | June 20, 2019 |
| NCT02086591 | Terminated | Phase 2 | A Phase II Study of Doxycycline in Relapsed NHL | March 2014 | November 2015 |
| NCT01163201 | Withdrawn | Phase 1/Phase 2 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | January 2014 | January 2015 |